Compare e l f Beauty Inc (ELF) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Mesoblast Limited — how do they compare? e l f Beauty Inc trades at $74.21 (market cap $4.37B), while Mesoblast Limited trades at $18.25 (market cap $2.31B). The key difference: e l f Beauty Inc is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals.
| ELF | MESO | |
|---|---|---|
Market Cap | $4.37B | $2.31B |
Sector | Technology | Technology |
52-Week High | $146.67 | $20.96 |
52-Week Low | $49.57 | $11.35 |
Enterprise Value | $5.00B | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO is trading at $18.61, up 11.17% today, with strong technical momentum as moving averages signal bullish conditions. The company shows promising revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a -144.33% net income margin. Recent milestones include completing patient recruitment for a Phase 3 chronic low back pain trial and securing a $50 million non-dilutive facility.
The outlook is cautiously optimistic given strong analyst support (45% buy ratings) and commercial progress, but significant execution risks remain. Investors face high valuation multiples (P/S 30.52) and substantial cash burn despite reduced operating expenses. The stock's near-term direction will depend on clinical trial outcomes and revenue acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
